Membrane lipid modifications and therapeutic effects mediated by hydroxydocosahexaenoic acid on Alzheimer's disease.

[1]  P. Escribá,et al.  Partitioning of liquid-ordered/liquid-disordered membrane microdomains induced by the fluidifying effect of 2-hydroxylated fatty acid derivatives. , 2013, Biochimica et biophysica acta.

[2]  R. Rial,et al.  Cognitive recovery and restoration of cell proliferation in the dentate gyrus in the 5XFAD transgenic mice model of Alzheimer’s disease following 2-hydroxy-DHA treatment , 2013, Biogerontology.

[3]  S. Niida,et al.  Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease , 2013, Lipids in Health and Disease.

[4]  G. Marfany,et al.  Specific sphingolipid content decrease in Cerkl knockdown mouse retinas. , 2013, Experimental eye research.

[5]  N. Hooper,et al.  Prion Protein-mediated Toxicity of Amyloid-β Oligomers Requires Lipid Rafts and the Transmembrane LRP1* , 2013, The Journal of Biological Chemistry.

[6]  K. Mullane,et al.  Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? , 2013, Biochemical pharmacology.

[7]  A. Gutiérrez,et al.  Defective lysosomal proteolysis and axonal transport are early pathogenic events that worsen with age leading to increased APP metabolism and synaptic Abeta in transgenic APP/PS1 hippocampus , 2012, Molecular Neurodegeneration.

[8]  J. García-Verdugo,et al.  2-Hydroxyoleic Acid Induces ER Stress and Autophagy in Various Human Glioma Cell Lines , 2012, PloS one.

[9]  Kirsten B. Holven,et al.  Fish Oil Supplementation Alters the Plasma Lipidomic Profile and Increases Long-Chain PUFAs of Phospholipids and Triglycerides in Healthy Subjects , 2012, PloS one.

[10]  M. Masserini,et al.  Binding of β-amyloid (1-42) peptide to negatively charged phospholipid membranes in the liquid-ordered state: modeling and experimental studies. , 2012, Biophysical journal.

[11]  M. Goedert,et al.  Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy , 2012, Brain : a journal of neurology.

[12]  D. Selkoe,et al.  Effects of membrane lipids on the activity and processivity of purified γ-secretase. , 2012, Biochemistry.

[13]  Bertram Wiedenmann,et al.  Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. , 2012, Prostaglandins & other lipid mediators.

[14]  S. Shaikh.  Biophysical and biochemical mechanisms by which dietary N-3 polyunsaturated fatty acids from fish oil disrupt membrane lipid rafts. , 2012, The Journal of nutritional biochemistry.

[15]  Christian Hölscher,et al.  GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease , 2012, Reviews in the neurosciences.

[16]  Oliver Wirths,et al.  Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease , 2012, Neurobiology of Aging.

[17]  Markus R Wenk,et al.  Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[18]  D. Selkoe,et al.  Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. , 2011, Archives of neurology.

[19]  Antonia Gutierrez,et al.  Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer’s mice hippocampus , 2011, Acta Neuropathologica.

[20]  D. Selkoe,et al.  Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. , 2011, Archives of neurology.

[21]  R. Rozmahel,et al.  DHA Supplemented in Peptamen Diet Offers No Advantage in Pathways to Amyloidosis: Is It Time to Evaluate Composite Lipid Diet? , 2011, PloS one.

[22]  T. Sacktor,et al.  Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer’s disease , 2011, Acta Neuropathologica.

[23]  M. Martín-Satué,et al.  Amyloid β peptide oligomers directly activate NMDA receptors. , 2011, Cell calcium.

[24]  F. Calon,et al.  DHA Improves Cognition and Prevents Dysfunction of Entorhinal Cortex Neurons in 3xTg-AD Mice , 2011, PloS one.

[25]  M. Péter,et al.  Docosahexaenoic Acid Reduces Amyloid β Production via Multiple Pleiotropic Mechanisms* , 2011, The Journal of Biological Chemistry.

[26]  R. Veerhuis,et al.  Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology. , 2011, CNS & neurological disorders drug targets.

[27]  F. Calon,et al.  Docosahexaenoic Acid-Derived Neuroprotectin D1 Induces Neuronal Survival via Secretase- and PPARγ-Mediated Mechanisms in Alzheimer's Disease Models , 2011, PloS one.

[28]  Michael Weiner,et al.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. , 2010, JAMA.

[29]  A. Blackwell,et al.  Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline , 2010, Alzheimer's & Dementia.

[30]  Carl W. Cotman,et al.  Deficient Liver Biosynthesis of Docosahexaenoic Acid Correlates with Cognitive Impairment in Alzheimer's Disease , 2010, PloS one.

[31]  Doriano Brogioli,et al.  Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. , 2010, Biomaterials.

[32]  Gopal Thinakaran,et al.  Membrane rafts in Alzheimer's disease beta-amyloid production. , 2010, Biochimica et biophysica acta.

[33]  A. Makriyannis,et al.  Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma , 2010, Journal of Lipid Research.

[34]  H. Su.  Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. , 2010, The Journal of nutritional biochemistry.

[35]  B. Levy.  Resolvins and protectins: natural pharmacophores for resolution biology. , 2010, Prostaglandins, leukotrienes, and essential fatty acids.

[36]  Marie Nguyen,et al.  A practical approach to RT-qPCR-Publishing data that conform to the MIQE guidelines. , 2010, Methods.

[37]  Seth Love,et al.  Fatty Acid Composition of Frontal, Temporal and Parietal Neocortex in the Normal Human Brain and in Alzheimer’s Disease , 2010, Neurochemical Research.

[38]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[39]  Markus Reischl,et al.  Zebrafish embryos as models for embryotoxic and teratological effects of chemicals. , 2009, Reproductive toxicology.

[40]  F. Nicoletti,et al.  β-Amyloid Monomers Are Neuroprotective , 2009, The Journal of Neuroscience.

[41]  Thomas Kolter,et al.  Principles of lysosomal membrane degradation: Cellular topology and biochemistry of lysosomal lipid degradation. , 2009, Biochimica et biophysica acta.

[42]  D. Selkoe,et al.  Direct and Potent Regulation of γ-Secretase by Its Lipid Microenvironment* , 2008, Journal of Biological Chemistry.

[43]  D. Hanger,et al.  Membrane‐bound β‐amyloid oligomers are recruited into lipid rafts by a fyn‐dependent mechanism , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  R. Vassar,et al.  BACE1 structure and function in health and Alzheimer's disease. , 2008, Current Alzheimer research.

[45]  F. Goñi,et al.  Triton X-100 partitioning into sphingomyelin bilayers at subsolubilizing detergent concentrations: effect of lipid phase and a comparison with dipalmitoylphosphatidylcholine. , 2007, Biophysical journal.

[46]  L. Lannfelt,et al.  Docosahexaenoic acid stimulates non‐amyloidogenic APP processing resulting in reduced Aβ levels in cellular models of Alzheimer's disease , 2007, The European journal of neuroscience.

[47]  P. Agostinho,et al.  Susceptibility of hippocampal neurons to Aβ peptide toxicity is associated with perturbation of Ca2+ homeostasis , 2007, Brain Research.

[48]  Frank M LaFerla,et al.  Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-β and Tau Pathology via a Mechanism Involving Presenilin 1 Levels , 2007, The Journal of Neuroscience.

[49]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[50]  O. Shido,et al.  Docosahexaenoic acid promotes neurogenesis in vitro and in vivo , 2006, Neuroscience.

[51]  J. F. López-Téllez,et al.  Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1×APP transgenic model of Alzheimer's disease , 2006, Neurobiology of Aging.

[52]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[53]  Lars-Olof Wahlund,et al.  Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. , 2006, Archives of neurology.

[54]  Elizabeth J Johnson,et al.  Potential role of dietary n-3 fatty acids in the prevention of dementia and macular degeneration. , 2006, The American journal of clinical nutrition.

[55]  M. P. Carrasco,et al.  Hexadecylphosphocholine disrupts cholesterol homeostasis and induces the accumulation of free cholesterol in HepG2 tumour cells. , 2006, Biochemical pharmacology.

[56]  P. Schwille,et al.  Lipids as Modulators of Proteolytic Activity of BACE , 2005, Journal of Biological Chemistry.

[57]  Charles N Serhan,et al.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. , 2005, The Journal of clinical investigation.

[58]  Takashi Morihara,et al.  A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model , 2005, The Journal of Neuroscience.

[59]  Ralph A. Nixon,et al.  Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study , 2005, Journal of neuropathology and experimental neurology.

[60]  R. Cowburn,et al.  The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation. , 2004, Biochemical and biophysical research communications.

[61]  D. Dickson,et al.  Dimeric Amyloid β Protein Rapidly Accumulates in Lipid Rafts followed by Apolipoprotein E and Phosphorylated Tau Accumulation in the Tg2576 Mouse Model of Alzheimer's Disease , 2004, The Journal of Neuroscience.

[62]  Thomas Klockgether,et al.  Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase , 2003, The Journal of Neuroscience.

[63]  D. Bennett,et al.  Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. , 2003, Archives of neurology.

[64]  B. Strooper,et al.  Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex , 2003, Neuron.

[65]  Hee-Yong Kim,et al.  Mechanisms of action of docosahexaenoic acid in the nervous system , 2001, Lipids.

[66]  P. Lantos,et al.  Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. , 1999, Journal of neuropathology and experimental neurology.

[67]  R. Gill,et al.  Regulation of expression and activity of distinct pRB, E2F, D-type cyclin, and CKI family members during terminal differentiation of P19 cells. , 1998, Experimental cell research.

[68]  M. Ruiz-Argüello,et al.  Different Effects of Enzyme-generated Ceramides and Diacylglycerols in Phospholipid Membrane Fusion and Leakage* , 1996, The Journal of Biological Chemistry.

[69]  K. Kristensson,et al.  Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease , 1991, Lipids.

[70]  T. Hagve,et al.  Peroxisomal retroconversion of docosahexaenoic acid (22:6(n-3)) to eicosapentaenoic acid (20:5(n-3)) studied in isolated rat liver cells. , 1991, Biochimica et biophysica acta.

[71]  L. Mayer,et al.  Vesicles of variable sizes produced by a rapid extrusion procedure. , 1986, Biochimica et biophysica acta.

[72]  A A Spector,et al.  Membrane lipid composition and cellular function. , 1985, Journal of lipid research.

[73]  R. Beninger,et al.  Differential effects of scopolamine on working and reference memory of rats in the radial maze , 1984, Pharmacology Biochemistry and Behavior.

[74]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[75]  N. Bogdanovic,et al.  PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. , 2011, Journal of Alzheimer's disease : JAD.

[76]  A. Llebaria,et al.  Synthesis and biological properties of Pachastrissamine (jaspine B) and diastereoisomeric jaspines. , 2009, Bioorganic & medicinal chemistry.

[77]  P. Escribá,et al.  Membrane-lipid therapy: a new approach in molecular medicine. , 2006, Trends in molecular medicine.

[78]  W. Markesbery,et al.  Regional Membrane Phospholipid Alterations in Alzheimer's Disease , 2004, Neurochemical Research.

[79]  B. de Strooper,et al.  Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. , 2003, Neuron.

[80]  Michael T Heneka,et al.  Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[81]  E. Coligan.  Current protocols in immunology , 1991 .